Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype.
Latent human immunodeficiency virus type 1 (HIV-1) persists even in patients treated with antiretroviral therapy. New treatment strategies are therefore needed to eradicate this latent viral reservoir without reducing immune cell function. We characterize the interleukin-7 (IL-7)-induced stimulation of primary human T cells and thymocytes and demonstrate, using the SCID-hu model, that IL-7 induces substantial expression of latent HIV while having minimal effects on the cell phenotype. Thus, IL-7 is a viable candidate to activate expression of latent HIV and may facilitate immune clearance of latently infected cells.
Scripture-Adams
Deirdre D
DD
Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA.
Brooks
David G
DG
Korin
Yael D
YD
Zack
Jerome A
JA
D000818:Animals; D023241:Antiretroviral Therapy, Highly Active; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D016130:Immunophenotyping; D015851:Interleukin-7 / Q000494:pharmacology*; D051379:Mice; D016513:Mice, SCID; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D017735:Virus Latency / Q000187:drug effects*
D015851:Interleukin-7